Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study

Lung Cancer

Volumn 67, Issue 1, 2010, Pages 114-119

  Zhang, Li ^a   Hou, Xue ^b   Lu, Shun ^b   Rao, Huilan ^a   Hou, Jinghui ^a   Luo, Rongzhen ^a   Huang, He ^a   Zhao, Hongyun ^a   Jian, Hong ^b   Chen, Zhiwei ^b   Liao, Meilin ^b   Wang, Xin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SHANGHAI CHEST HOSPITAL   (China)

Author keywords

Bone metastasis; Bone sialoprotein; Non small cell lung cancer; Osteopontin

Indexed keywords

BONE SIALOPROTEIN; OSTEOPONTIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; RETROSPECTIVE STUDIES; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 71549121372     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.03.017     Document Type: Article

References (45)

1. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
2. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16 (1998) 593-602
3. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
4. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100 (2004) 2613-2621
5. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., and Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008-2012
6. Horak C.E., and Steeg P.S. Metastasis gets site specific. Cancer Cell 8 (2005) 93-95
7. Cho N.H., Hong K.P., Hong S.H., Kang S., Chung K.Y., and Cho S.H. MMP expression profiling in recurred stage IB lung cancer. Oncogene 23 (2004) 845-851
8. Takenaka K., Ishikawa S., Kawano Y., Yanagihara K., Miyahara R., Otake Y., et al. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer 40 (2004) 1617-1623
9. Fedarko N.S., Jain A., Karadag A., Van Eman M.R., and Fisher L.W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7 (2001) 4060-4066
10. Sasaki H., Yu C.Y., Dai M., Tam C., Loda M., Auclair D., et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat 77 (2003) 245-252
11. Littlewood-Evans A.J., Bilbe G., Bowler W.B., Farley D., Wlodarski B., Kokubo T., et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57 (1997) 5386-5390
12. Brubaker K.D., Vessella R.L., True L.D., Thomas R., and Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18 (2003) 222-230
13. Ganss B., Kim R.H., and Sodek J. Bone sialoprotein. Crit Rev Oral Biol Med 10 (1999) 79-98
14. Hunter G., and Goldberg H. Modulation of crystal formation by bone phosphoproteins: role of glutamic acid-rich sequences in the nucleation of hydroxypatite by bone sialoprotein. J Biol Chem 302 (1994) 175-179
15. Sodek J., Ganss B., and McKee M.D. Osteopontin. Crit Rev Oral Biol Med 11 (2000) 279-303
16. Waltregny D., Bellahcène A., Van Riet I., Fisher L.W., Young M., Fernandez P., et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 90 (1998) 1000-1008
17. Bellahcène A., Kroll M., Liebens F., and Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 11 (1996) 665-670
18. Ibrahim T., Leong I., Sanchez-Sweatman O., Khokha R., Sodek J., Tenenbaum H.C., et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 18 (2000) 253-260
19. Waltregny D., Bellahcène A., de Leval X., Florkin B., Weidle U., and Castronovo V. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15 (2000) 834-843
20. Ihara H., Denhardt D.T., Furuya K., Yamashita T., Muguruma Y., Tsuji K., et al. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 276 (2001) 13065-13071
21. Hotte S.J., Winquist E.W., Stitt L., Wilson S.M., and Chambers A.F. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95 (2002) 506-512
22. Bellahcène A., Castronovo V., Ogbureke K.U.E., Fisher L.W., and Fedarko N.S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8 3 (2008) 212-226
23. Papotti M., Kalebic T., Volante M., Chiusa L., Bacillo E., Cappia S., et al. Bone sialoprotein is predictive of bone metastasis in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol 24 (2007) 4818-4824
24. Carlinfante G., Vassiliou D., Svensson O., Wendel M., Heinegård D., and Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20 (2003) 437-444
25. Torhorst J., Bucher C., and Kononen J. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159 (2001) 2249-2256
26. Gillett C.E., Springall R.J., Barnes D.M., and Hanby A.M. Multiple tissue core arrays in histopathology research: a validation study. J Pathol 192 (2000) 549-553
27. Camp R.L., Charette L.A., and Rimm D.L. Validation of tissue microarray technology in breast carcinoma. Lab Invest 80 (2000) 1943-1949
28. Heinegard D., Andersson G., and Reinholt F.P. Roles of osteopontin in bone remodeling. Ann N Y Acad Sci 760 (1995) 213-222
29. Thalmann G.N., Sikes R.A., Devoll R.E., Kiefer J.A., Markwalder R., Klima I., et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5 (1999) 2271-2277
30. Bellahcène A., Maloujahmoum N., and Fisher L.W. Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 61 (1997) 183-188
31. Diel I.J., Solomayer E.F., Seibel M.J., Pfeilschifter J., Maisenbacher H., Gollan C., et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5 (1999) 3914-3919
32. Sung V., Stubbs III J.T., Fisher L., Aaron A.D., and Thompson E.W. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 176 (1998) 482-494
33. Yoneda T., and Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328 (2005) 679-687
34. Donati V., Boldrini L., Dell'Omodarme M., Prati M.C., Faviana P., Camacci T., et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11 (2005) 6459-6465
35. Boldrini L., Donati V., Dell'Omodarme M., Prati M.C., Faviana P., Camacci T., et al. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93 (2005) 453-457
36. Philip Y.W., and Paul C.K. The role of osteopontin in tumor metastasis. J Surg Res 121 (2004) 228-241
37. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthesis in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296 (2001) 235-242
38. Benford H.L., McGowan N.W., Helfrich M.H., Nuttall M.E., Rogers M.J., et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28 (2001) 465-473
39. Bezzi M., Hasmim M., Bieler G., Dormond O., and Rüegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 278 (2003) 43603-43614
40. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami-H A., and Croucher P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84 (2001) 1126-1134
41. Matsumoto S., Kimura S., Segawa H., Kuroda J., Yuasa T., Sato K., et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47 (2005) 31-39
42. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538-6544
43. Santini D., Vincenzi B., Dicuonzo G., Scarpa S., and Baldi A. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9 (2003) 2893-2897
44. Mystakidou K., Katsouda E., Parpa E., Kelekis A., Galanos A., and Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 22 (2005) 195-201
45. Michaelson M.D., and Smith M.R. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23 (2005) 8219-8224